Tandutinib (MLN518) , ≥98% , 387867-13-2

CAS NO.：387867-13-2

Empirical Formula: C31H42N6O4

Molecular Weight: 562.7

MDL number: MFCD09954147

PRODUCT Properties

• Melting point: 177-178°C
• Boiling point: 769.5±60.0 °C(Predicted)
• Density: 1.213±0.06 g/cm3(Predicted)
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Chloroform (Slightly), Methanol (Slightly)
• form: Solid
• pka: 13.39±0.70(Predicted)
• color: White to Off-White
• Water Solubility: H2O: 2mg/mL, clear
• InChIKey: UXXQOJXBIDBUAC-UHFFFAOYSA-N
• SMILES: N1(C(NC2=CC=C(OC(C)C)C=C2)=O)CCN(C2=C3C(=NC=N2)C=C(OCCCN2CCCCC2)C(OC)=C3)CC1
• CAS DataBase Reference: 387867-13-2(CAS DataBase Reference)

Description and Uses

Tandutinib is a potent antagonist of platelet-derived growth factor receptor β (PDGFRβ), FLT3, and c-Kit (IC₅₀ = 200, 220, and 170 nM, respectively). It less potently inhibits macrophage colony-stimulating factor 1 receptor (IC₅₀ = 3.4 μM) and does not significantly inhibit other tyrosine or serine/threonine kinases. Tandutinib blocks the growth of cells expressing an internal tandem duplication within the juxtamembrane domain of the FLT3 receptor, found in some acute myelogenous leukemia cells. It also impairs the growth of colon cancer cells through its actions on the c-Kit receptor. Tandutinib reverses multidrug resistance in vitro by impairing the efflux activity of the multidrug resistance protein 7.

An oral, small-molecule inhibitor of FLT3 for the treatment of AML (acute myelogenous leukemia) clinical trials in patients with AML and myelodysplastic syndrome, but displayed promising antileukemic activity (90% complete remissions) in a phase I/II trial in patients with newly diagnosed AML w hen administered in combination with cytarabine and daunorubicin.